Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transdermal nicotine and Down's syndrome

This article was originally published in The Tan Sheet

Executive Summary

Cognitive improvements were found in five retarded individuals subjected to auditory response tests after being given 5 mg of transdermal nicotine for two hours, University of Austria, Vienna researchers report in the Oct. 21 Lancet. The study, conducted by Rainer Seidl, MD, et al., found "improvements possibly related to attention and information processing" in a group of five 18-34 year old patients with Down's syndrome in relation to controls. Seidl et al. note due to the small study size, results cannot be generalized, and the effects of higher nicotine doses are not known. Nicotine patches were provided by Pharmacia





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts